GE HealthCare in April forecast adjusted earnings per-share between $3.90 and $4.10 and free cash flow of at least $1.2 billion. This compared to previous guidance of adjusted earnings between $4.61 a ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Incyte Corp's new chief executive, Bill Meury, outlined a growth strategy on Tuesday focused on accelerating drug development and prudent capital allocation, as the company faces the looming patent ...